PI3K in lymphocyte development, differentiation and activation

Nature Reviews Immunology

Volumn 3, Issue 4, 2003, Pages 317-330

  Okkenhaug, Klaus ^a   Vanhaesebroeck, Bart ^b  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CD28 ANTIGEN; PROTEIN TYROSINE KINASE;

AUTOIMMUNITY; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVE SITE; GENE TARGETING; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION; CYTOLOGY; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD28; B-LYMPHOCYTES; CELL DIFFERENTIATION; ENZYME ACTIVATION; GENE TARGETING; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MODELS, IMMUNOLOGICAL; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0038549067     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1056     Document Type: Review

References (151)

1. Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602 (2001).
2. Vanhaesebroeck, B., Leevers, S. J., Panayotou, G. & Waterfield, M. D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22, 257-272 (1997).
3. Vanhaesebroeck, B. & Alessi, D. R. The PI3K-PDK1 connection more than just a road to PKB. Biochem. J. 346, 551-576 (2000).
4. 3 levels: viability of flies lacking PTEN restored by a PH-domain mutation in Akt/PKB. Science 295, 2088-2091 (2002).
5. Schaeffer, E. M. & Schwartzberg, P. L. Tec-family kinases in lymphocyte signaling and function. Curr. Opin. Immunol. 12, 282-288 (2000).
6. Simonsen, A., Wurmser, A. E., Emr, S. D. & Stenmark, H. The role of phosphoinositides in membrane transport. Curr. Opin. Cell Biol. 13, 485-492 (2001).
7. Astoul, E., Edmunds, C., Cantrell, D. A. & Ward, S. G. PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol. 22, 490-496 (2001).
8. Arcaro, A. & Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-triphosphate in neutrophil responses. Biochem J. 296, 297-301 (1993).
9. Vlahos, C. J., Matter, W. F., Hui, K. Y. & Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248 (1994).
10. Gunther, R., Kishore, P. N., Abbas, H. K. & Mirocha, C. J. Immunosuppressive effects of dietary wortmannin on rats and mice. Immunopharmacol. Immunotoxicol. 11, 559-570 (1989).
11. Gunther, R., Abbas, H. K. & Mirocha, C. J. Acute pathological effects on rats of orally administered wortmannin-containing preparations and purified wortmannin from Fusarium oxysporum. Food Chem. Toxicol. 27, 173-179 (1989).
12. Fruman, D. A. et al. Impaired B-cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283, 393-397 (1999).
13. Suzuki, H. et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 283, 390-392 (1999). References 12 and 13 were the first to report an Xid-like phenotype of p85α-deficient mice.
14. Yu, J. et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18, 1379-1387 (1998).
15. Lu-Kuo, J. M., Fruman, D. A., Joyal, D. M., Cantley, L. C. & Katz, H. R. Impaired kit- but not FcεRI-initiated mast-cell activation in the absence of phosphoinositide 3-kinase p85α gene products. J. Biol. Chem. 275, 6022-6029 (2000).
16. Terauchi, Y. et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nature Genet 21, 230-235 (1999).
17. Fruman, D. A. et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85α. Nature Genet. 26, 379-382 (2000).
18. Ueki, K. et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell Biol. 22, 965-977 (2002).
19. Ueki, K. et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 99, 419-424 (2002).
20. Jimenez, C. et al. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J. Cell. Biol. 151, 249-262 (2000).
21. Kang, H., Schneider, H. & Rudd, C. E. Phosphatidylinositol 3-kinase p85 adaptor function in T cells. Co-stimulation and regulation of cytokine transcription independent of associated p110. J. Biol. Chem. 277, 912-921 (2002).
22. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963-10968 (1999).
23. Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI3-kinase. Mamm. Genome 13, 169-172 (2002).
24. Okkenhaug, K. et al. Impaired B- and T-cell antigen receptor signaling in p110δ PI3-kinase mutant mice. Science 297, 1031-1034 (2002).
25. Clayton, E. et al. A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B-cell development and activation. J. Exp. Med. 196, 753-763 (2002).
26. Jou, S.-T. et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591 (2002). References 24-26 indicated a non-redundant role for p110δ in B-cell activation. Reference 24 also showed that p110δ is required for T-cell activation.
27. Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase-γ in inflammation. Science 287, 1049-1053 (2000).
28. Li, Z. et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046-1049 (2000).
29. Sasaki, T. et al. Function of PI3Kγ in thymocyte development. T-cell activation and neutrophil migration. Science 287, 1040-1046 (2000). References 27-29 showed a crucial role for p110γ in neutrophil and macrophage function. Sasaki et al. also presented evidence of reduced T-cell function in p110γ-deficient mice.
30. Laffargue, M. et al Phosphoinositide 3-kinase γ is an essential amplifier of mast-cell function. Immunity 16, 441-451 (2002).
31. Hirsch, E. et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J. 15, 2019-2021 (2001).
32. Crackower, M. A. et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737-749 (2002).
33. Sasaki, T., Suzuki, A., Sasaki, J. & Penninger, J. M. Phosphoinositide 3-kinases in immunity: lessons from knockout mice. J. Biochem. (Tokyo) 131, 495-501 (2002).
34. Okkenhaug, K. & Vanhaesebroeck, B. PI3K-signalling in B and T cells: insights from gene-targeted mice. Biochem. Soc. Trans. 31, 270-274 (2003).
35. Rickert, R. C., Rajewsky, K. & Roes, J. Impairment of T-cell-dependent B-cell responses and B-1-cell development in CD19-deficient mice. Nature 376, 352-355 (1995).
36. Martin, F. & Kearney, J. F. Positive selection from newly formed to marginal-zone B cells depends on the rate of clonal production, CD19 and btk. Immunity 12, 39-49 (2000).
37. Tuveson, D. A., Carter, R. H., Soltoff, S. P. & Fearon, D. T. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260, 986-989 (1993).
38. Wang, Y. et al. The physiologic role of CD19 cytoplasmic tyrosines. Immunity 17, 501-514 (2002). This study indicates that phosphoinositide 3-kinase (PI3K) is the main mediator of CD19 function.
39. Otero, D. C., Anzelon, A. N. & Rickert, R. C. CD19 function in early and late B-cell development. I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J. Immunol. 170, 73-83 (2003).
40. Cariappa, A. et al. The follicular versus marginal-zone B-lymphocyte cell-fate decision is regulated by Aiolos, Btk and CD21. Immunity 14, 603-615 (2001).
41. Carter, R. H. & Fearon, D. T. CD19: lowering the threshold for antigen-receptor stimulation of B lymphocytes. Science 256, 105-107 (1992).
42. Fujimoto, M. et al. Complementary roles for CD19 and Bruton's tyrosine kinase in B-lymphocyte signal transduction. J. Immunol. 168, 5465-5476 (2002).
43. Otero, D. C., Omori, S. A. & Rickert, R. C. Cd19-dependent activation of Akt kinase in B-lymphocytes. J. Biol. Chem. 276, 1474-1478 (2001).
44. Tengholm, A. & Meyer, T. A PI3-kinase signaling code for insulin-triggered insertion of glucose transporters into the plasma membrane. Curr. Biol. 12, 1871-1876 (2002). In this paper, Tengholm et al. used evanescent field microscopy to reveal a PI3K signalling code.
45. Anzelon, A. N., Wu, H. & Rickert, R. C. Pten inactivation Alters peripheral B-lymphocyte fate and reconstitutes CD19 function. Nature Immunol. 4, 287-294 (2003). PTEN deficiency rescues the CD19-deficient phenotype, providing additional evidence of a crucial role for PI3K in CD19 signalling. See also note added in proof.
46. Gold, M. R. & Aebersold, R. Both phosphatidylinositol 3-kinase and phosphatidylinositol 4-kinase products are increased by antigen-receptor signaling in B cells. J. Immunol. 152, 42-50 (1994).
47. Astoul, E., Watton, S. & Cantrell, D. The dynamics of protein kinase B regulation during B-cell antigen receptor engagement. J. Cell Biol. 145, 1511-1520 (1999). In references 47 and 77, green fluorescent protein (GFP)-PH domains were used to visualize PI3K signalling in B-cell lines. See also references 103 and 104 for similar work in transgenic T cells.
48. Okada, T., Maeda, A., Iwamatsu, A., Gotoh, K. & Kurosaki, T. BCAP: the tyrosine kinase substrate that connects B-cell receptor to phosphoinositide 3-kinase activation. Immunity 13, 817-827 (2000).
49. Inabe, K. & Kurosaki, T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 99, 584-589 (2002).
50. Yamazaki, T. et al. Essential immunoregulatory role for BCAP in B-cell development and function. J. Exp. Med. 195, 535-545 (2002).
51. Han, J. et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279, 558-560 (1998).
52. Inabe, K. et al. Vav3 modulates B-cell receptor responses by regulating phosphoinositide 3-kinase activation. J. Exp. Med. 195, 189-200 (2002). This paper indicates that VAV acts upstream, rather than downstream, of the PI3K signalling pathway.
53. Suzuki, H. et al. PI3K and Btk differentially regulate B-cell antigen receptor-mediated signal transduction. Nature Immunol. 4, 280-286 (2003). The authors of this paper propose that BTK acts in a pathway parallel to PI3K, rather than downstream of PI3K as was previously assumed. This is a provocative, but highly controversial, issue.
54. 3 levels in extracts of cells without the need for metabolic labelling.
55. Satterthwaite, A. B., Li, Z. & Witte, O. N. Btk function in B-cell development and response. Semin. Immunol. 10, 309-316 (1998).
56. Marshall, A. J., Niiro, H., Yun, T. J. & Clark, E. A. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cγ pathway. Immunol. Rev. 176, 30-46 (2000).
57. 3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell 94, 5-8 (1998).
58. Rawlings, D. J. et al. Activation of BTK by a phosphorylation mechanism initiated by SRC-family kinases. Science 271, 822-825 (1996).
59. Park, H., et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 4, 515-525 (1996).
60. Nisitani, S., Kato, R. M., Rawlings, D. J., Witte, O. N. & Wahl, M. I. In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies. Proc. Natl Acad. Sci. USA 96, 2221-2226 (1999).
61. Fruman, D. A. et al. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proc. Natl Acad. Sci. USA 99, 359-364 (2002).
62. Marshall, A. J. et al. A novel B lymphocyte-associated adaptor protein, Bam32, regulates antigen receptor signaling downstream of phosphatidylinositol 3-kinase. J. Exp. Med. 191, 1319-1332 (2000).
63. 3-binding protein (BAM32) that seems to regulate PLCγ.
64. Gold, M. R. et al. Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase. Immunol. Rev. 176, 47-68 (2000).
65. Turner, M. & Billadeau, D. D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nature Rev. Immunol. 2, 476-486 (2002).
66. Isakoff, S. J. et al. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J. 17, 5374-5387 (1998).
67. Palmby, T. R., Abe, K. & Der, C. J. Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity. J. Biol. Chem. 277, 39350-39359 (2002).
68. Baumeister, M. A. et al. Loss of PtdIns-3-P binding by the C-terminal Tiam-1 pleckstrin homology (PH) domain prevents in vivo Rac1 activation without affecting membrane targeting. J. Biol. Chem. 13 January 2003 (DOI: 10.1074/jbc M211901200).
69. Lemmon, M. A. & Ferguson, K. M. Signal-dependent membrane targeting by pleckstrin homology (PH) domains Biochem. J. 350, 1-18 (2000).
70. 2+ flux. Curr. Biol. 10, 393-396 (2000).
71. Jacob, A., Cooney, D. Tridandapani, S., Kelley, T. & Coggeshall, K. M. FcγRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells J. Biol. Chem. 274, 13704-13710 (1999).
72. Bolland, S., Pearse, R. N., Kurosaki, T. & Ravetch, J. V. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8, 509-516 (1998).
73. 3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 17, 1961-1972 (1998).
74. Liu, Q. et al. The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B-cell antigen receptor signaling. J. Exp. Med. 188, 1333-1342 (1998).
75. Helgason, C. D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610-1620 (1998).
76. Brauweiler, A. et al. Differential regulation of B-cell development, activation, and death by the SRC homology 2 domain-containing 5′ inositol phosphatase (SHIP). J. Exp. Med. 191, 1545-1554 (2000). References 74-76 describe the autoimmune phenotype of SHIP-deficient mice, which is due, in part, to hyperactive B cells.
77. Marshall, A. J., Krahn, A. K., Ma, K., Duronio, V. & Hou, S. TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma-membrane recruitment triggered by the B-cell antigen receptor. Mol. Cell Biol. 22, 5479-5491 (2002).
78. Dowler, S. et al. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. Biochem. J. 351, 19-31 (2000).
79. Stefanova, I., Dorfman, J. R. & Germain, R. N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420, 429-434 (2002).
80. Murphy, K. M. & Reiner S. L. Decision making in the immune system: the lineage decisions of helper T cells. Nature Rev. Immunol. 2, 933-944 (2002).
81. Sprent, J. & Surh, C. D. T-cell memory. Annu. Rev. Immunol. 20, 551-579 (2002).
82. Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 82-86 (1998).
83. Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature Rev. Immunol. 2, 116-126 (2002).
84. Fruman, D. A. Satterthwaite, A. B. & Witte, O. N. Xid-like phenotypes: a B-cell signalosome takes shape. Immunity 13, 1-3 (2000).
85. Maloy, K. J. & Powrie, F. Regulatory T cells in the control of immune pathology. Nature Immunol. 2, 816-822 (2001).
86. H2 cytokines. Nature Immunol. 2, 37-44 (2001).
87. + T cells. Immunity 11, 399-409 (1999).
88. Schaeffer, E. M. et al. Mutation of Tec-family kinases alters T-helper cell differentiation. Nature Immunol. 2, 1183-1188 (2001). References 86-88 link PI3K to T-cell differentiation by showing involvement of the PI3K effectors AKT/PKB and ITK.
89. Ward, S. G., Westwick, J., Hall, N. D. & Sansom, D. M. Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T-cell receptor/CD3 activation. Eur. J. Immunol. 23, 2572-2577 (1993).
90. Costello, P. S., Gallagher, M. & Cantrell, D. A. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nature Immunol. 3, 1082-1089 (2002).
91. Harriague, J. & Bismuth, G. Imaging antigen-induced PI3K activation in T cells. Nature Immunol, 3, 1090-1096 (2002). In references 90 and 91, GFP-PH chimaeric proteins were used to visualize PI3K signalling in T cells, yielding some surprising results.
92. Ward, S. G. & Cantrell, D. A. Phosphoinositide 3-kinases in T-lymphocyte activation. Curr. Opin. Immunol. 13, 332-338 (2001).
93. Bruyns, E. et al. T-cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-ζ complex, recruits intracellular signaling proteins to the plasma membrane. J. Exp. Med. 188, 561-575 (1998).
94. Zhang, W., Sloan, L. J., Kitchen, J., Trible, R. P. & Samelson, L. E. LAT: the ZAP-70 tyrosine kinase substrate that links T-cell receptor to cellular activation. Cell 92, 83-92 (1998).
95. Reynolds, L. F. et al. Vav1 transduces T-cell receptor signals to the activation of phospholipase C-γ1 via phosphoinositide 3-kinase-dependent and -independent pathways. J. Exp. Med. 195, 1103-1114 (2002). Reference 95 places VAV1 between T-cell receptor and PI3K signalling. Previous studies had placed VAV downstream, rather than upstream, of PI3K.
96. Exley, M. & Varticovski, L. Evidence for phosphatidylinositol 3-kinase-dependent T-cell antigen receptor (TCR) signal transduction. Mol. Immunol. 34, 221-226 (1997).
97. Eder, A. M., Dominguez, L., Franke, T. F. & Ashwell, J. D. Phosphoinositide 3-kinase regulation of T-cell receptor-mediated interleukin-2 gene expression in normal T cells. J. Biol. Chem. 273, 28025-28031 (1998).
98. Liu, K. Q., Bunnell, S. C., Gurniak, C. B. & Berg, L. J. T-cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J. Exp. Med. 187, 1721-1727 (1998).
99. Liao, X. C. et al. Itk negatively regulates induction of T-cell proliferation by CD28 costimulation. J. Exp. Med. 186, 221-228 (1997).
100. Chamorro, M. et al. Requirements for activation and RAFT localization of the T-lymphocyte kinase RIk/Txk. BMC Immunol. 2, 3 (2001).
101. Schaeffer, E. M. et al. Requirement for Tec kinases RIk and Itk in T-cell receptor signaling and immunity. Science 264, 638-641 (1999).
102. + T cells. J. Immunol. 158, 4688-4695 (1997).
103. Viola, A., Schroeder, S., Sakakibara, Y. & Lanzavecchia, A T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283, 680-682 (1999).
104. Xavier, R., Brennan, T., Li, Q., McCormack, C. & Seed, B. Membrane compartmentation is required for efficient T-cell activation. Immunity 8, 723-732 (1998).
105. Ward, S. G., June, C. H. & Olive, D. PI 3-kinase: a pivotal pathway in T-cell activation? Immunol. Today 17, 187-197 (1996).
106. Pages, F. et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369, 327-329 (1994).
107. Okkenhaug, K. et al. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nature Immunol. 2, 325-332 (2001).
108. Harada, Y. et al. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J. Immunol. 166, 3797-3803 (2001).
109. L. J. Immunol. 166, 5331-5335 (2001). References 107-109 provide evidence of a crucial role for PI3K in transmitting survival signals, but not necessarily signals for the production of IL-2 or proliferation.
110. L levels in vivo. J. Exp. Med. 191, 1721-1734 (2000).
111. L. Immunity 3, 87-98 (1995).
112. L restores cell survival, but not proliferation off effector differentiation, in CD28-deficient T lymphocytes. J. Exp. Med. 191, 2031-2038 (2000).
113. Kim, H. H., Tharayil, M. & Rudd, C. E. Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling. J. Biol. Chem. 273, 296-301 (1998).
114. Okkenhaug, K. & Rottapel, R. Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction. J. Biol. Chem. 273, 21194-21202 (1998).
115. Holdorf, A. D. et al. Proline residues in CD28 and the Src homology (SH) 3 domain of Lck are required for T-cell costimulation. J. Exp. Med. 190, 375-384 (1999).
116. Marengere, L. E. et al. The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T-cell costimulatory receptor CD28. J. Immunol. 159, 3220-3229 (1997).
117. Pages, F. et al. Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association. J. Biol. Chem. 271, 9403-9409 (1996).
118. Prasad, K. V. S. et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl Acad. Sci. USA 91, 2834-2838 (1994).
119. Truitt, K. E., Hicks, C. M. & Imboden, J. B. Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J. Exp. Med. 179, 1071-1076 (1994).
120. Cai, Y. C. et al. Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity 3, 417-426 (1995).
121. Holdorf, A. D. Lee, K. H., Burack, W. R., Allen, P. M. & Shaw, A. S. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nature Immunol. 3, 259-264 (2002).
122. Moarefi, I. et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385, 650-653 (1997).
123. Andreotti, A. H., Bunnell, S. C., Feng, S., Berg, L. J. & Schreiber, S. L. Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature 385, 93-97 (1997).
124. Sathish, J. G. et al. Requirement for CD28 co-stimulation is lower in SHP-1-deficient T cells. Eur. J. Immunol. 31, 3649-3658 (2001).
125. Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769-777 (2002).
126. Maehama, T. & Dixon, J. E. EPTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9, 125-128 (1999).
127. Cantley, L. C. & Neel, B. G. New insights into tumor suppression PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240-4245 (1999).
128. +/- mice. Science 285, 2122-2125 (1999).
129. Suzuki, A. et al. T-cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523-534 (2001). References 128 and 129 show that unrestrained PI3K signalling as a consequence of reduced or absent PTEN expression by T cells leads to autoimmune disease and leukaemia.
130. Borlado, L. R. et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14, 895-903 (2000).
131. Jensen, W. A. Marschner, S., Ott, V. L. & Cambier, J. C. FcγRIIB-mediated inhibition of T-cell receptor signal transduction involves the phosphorylation of SH2-containing inositol 5-phosphatase (SHIP), dephosphorylation of the linker of activated T-cells (LAT) and inhibition of calcium mobilization. Biochem. Soc Trans. 29, 840-846 (2001).
132. Freeburn, R. W. et al. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J. Immunol. 169, 5441-5450 (2002).
133. Whitman, M., Downes, C. P., Keeler, M., Keller, T. & Cantley, L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332, 644-646 (1988).
134. Stein, R. C. & Waterfield, M. D. PI3-kinase inhibition: a target for drug development? Mol. Med. Today 6, 347-357 (2000).
135. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G. & Staunton, D. E. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol. 170, 2647-2654 (2003).
136. Sawyer, C. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p1105. Cancer Res. (in the press).
137. Tolias, K. F., Cantley, L. C. & Carpenter, C. L. Rho family GTPases bind to phosphoinositide kinases. J. Biol. Chem. 270, 17656-17659 (1995).
138. Zheng, Y., Bagrodia, S. & Cerione, R. A. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J. Biol. Chem. 269, 18727-18730 (1994).
139. Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532 (1994).
140. Stephens, L. R. et al. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105-114 (1997).
141. Hardy, R. R. & Hayakawa, K. B-cell development pathways. Annu. Rev. Immunol. 19, 595-621 (2001).
142. Myers, M. G. Jr et al. Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1 and interleukin-4 stimulation. J. Biol. Chem. 269, 28783-28789 (1994).
143. Bone, H. & Williams, N. A. Antigen-receptor cross-linking and lipopolysaccharide trigger distinct phosphainositide 3-kinase-dependent pathways to NF-κB activation in primary B cells. Int. Immunol. 13, 807-816 (2001).
144. Arbibe, L. et al. Toll-like receptor 2-mediated NF-κB activation requires a Rac1-dependent pathway. Nature Immunol. 1, 533-540 (2000).
145. Andjelic, S. et al. Phosphatidylinositol 3-kinase and NF-κB/ Rel are at the divergence of CD40-mediated proliferation and survival pathways. J. Immunol. 165, 3860-3867 (2000).
146. Arron, J. R. et al. A positive regulatory role for Cbl-family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J. Biol. Chem. 276, 30011-30017 (2001).
147. Kurosaki, T. Regulation of B-cell signal transduction by adaptor proteins. Nature Rev. Immunol. 2, 354-363 (2002).
148. Genot, E. M. et al. The T-cell receptor regulates Akt (protein kinase B) via a pathway involving Rac 1 and phosphatidylinositide 3-kinase Mol. Cell Biol. 20, 5469-5478 (2000).
149. Kane, L. P., Lin, J. & Weiss. A It's all Rel-ative: NF-κB and CD28 costimulation of T-cell activation. Trends Immunol. 23, 413-420 (2002).
150. Jacinto, E. & Hall, M. N. Tor signalling in bugs, brain and brawn. Nature Rev. Mol. Cell Biol. 4, 117-126 (2003).
151. Suzuki, A. et al. Critical roles of Pten in B-cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 197, 657-667 (2003).